Topline Capital Management’s Nephros NEPH Stock Holding History

Topline Capital Management’s Portfolio NEPH Stock Details NEPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.91M	Sell	535,698 -46,269	-8%	-$150K	0.5%	24
2026 Q1	$1.73M	Sell	581,967 -32,335	-5%	-$129K	0.29%	31
2025 Q4	$3M	Buy	614,302 +18,002	+3%	+$92K	0.27%	35
2025 Q3	$2.82M	Buy	596,300 +118,851	+25%	+$467K	0.48%	28
2025 Q2	$1.95M	Buy	477,449 +55,360	+13%	+$148K	0.33%	30
2025 Q1	$726K	Buy	422,089 +2,202	+0.5%	+$3.45K	0.17%	34
2024 Q4	$617K	Buy	+419,887	New	+$640K	0.12%	33

Other funds holding NEPH

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cornerstone Capital Palo Alto, California $1.12B AUM 28.84% 1-Year Est. Return

Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MFIM

Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return

HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return

Navellier & Associates Reno, Nevada $1.26B AUM 95.39% 1-Year Est. Return

Topline Capital Management's NEPH Position: Q2 2026 in Review

Topline Capital Management reduced its Nephros (NEPH) stake by 8% in Q2 2026, selling an estimated $150K and leaving 535,698 shares worth $1.91M. The position accounts for 0.5% of the portfolio, ranked #24.

Topline Capital Management first reported a position in NEPH in Q4 2024 and has held it in 7 quarters since. The position peaked at $3M in Q4 2025. 33 funds tracked by Wall St. Rank hold NEPH as of Q2 2026.

Topline Capital Management held 535,698 shares of Nephros worth $1.91M as of Q2 2026.
Topline Capital Management sold 46,269 Nephros shares in Q2 2026, an estimated $150K.
Nephros made up 0.5% of Topline Capital Management's portfolio in Q2 2026, its #24 holding.
Topline Capital Management first reported a position in Nephros in Q4 2024 and has held it in 7 quarters since.
Topline Capital Management's Nephros position peaked at $3M in Q4 2025.
33 funds tracked by Wall St. Rank held Nephros as of Q2 2026.

Based on Topline Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.